Samarth Kulkarni

CEO and Chairman at CRISPR Therapeutics @CRISPRTX, which is pioneering a new era of gene-based medicines. Tweets are my own.

[avidresearch @avidresearch]

$BDTX and $AVBP comparable based on mPFS.

$BDTX clear advantage in CNS metastases ?

“Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases”

[Alex Harding @AlexHarding7]

I am extremely skeptical of the long-term prospects for in vivo gene therapy with viral vectors that do random or semi-random integration.

[Samarth Kulkarni @CrisprSam]

Congrats to Kathy High and Stu Orkin (and their colleagues) on winning the Breakthrough Prize, both of whom I’ve had the pleasure of working closely with! Luxturna and Casgevy are groundbreaking therapies that will pave the way for many more.

[Centessa Pharmaceuticals @centessa]

Centessa has entered a definitive agreement to be acquired by @EliLillyandCo. To our team, investigators, patients, and advocates: thank you!

Please refer to today’s full announcement for key information and cautionary statements: https://t.co/WdOJsYdqQ3

[Samarth Kulkarni @CrisprSam]

Today we shared an update on zugo-cel (formerly CTX112) - best-in-class allogeneic CD19 CART! The data reflect encouraging progress across autoimmune disease and hematologic malignancies and support the continued advancement of zugo-cel across multiple disease settings. @CRISPRTX

[CRISPR Therapeutics @CRISPRTX]

Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. Learn more here: https://t.co/eYb2rDwtKv

[Samarth Kulkarni @CrisprSam]

@VertexPharma and @CRISPRTX new data in children ages 5-11 with SCD or TDT were presented today at #ASH25, opening up the possibility of treating these conditions earlier in life.

[Samarth Kulkarni @CrisprSam]

#AHA25 and @NEJM data for CTX310 by @ProfSNicholls . A single in vivo administration safely and durably lowered ANGPTL3, reducing triglycerides and LDL, progress toward applying gene editing to more common diseases. @CRISPRTX

[Samarth Kulkarni @CrisprSam]

Pleased that the FDA has included CASGEVY for patients with SCD and TDT in the CNPV pilot program, recognizing its potential clinical benefit and the importance of early intervention to help change the course of these diseases. @CRISPRTX $crsp

[Samarth Kulkarni @CrisprSam]

Enjoyed this discussion with @Nimish1316 on the gene editing space and the biotech sector at large! I've gotten a chance to work closely with Nimish on Oruka Tx

[Venrock @Venrock]

🎙On our latest episode of Running Through Walls, @Nimish1316 speaks with @CRISPRTX CEO & Chairman @CrisprSam about their incredible gene-editing platform and his advice for building businesses around life-changing science. Listen more here: https://t.co/1QaV36YhiS

[Samarth Kulkarni @CrisprSam]

Fully agree with Bob

[Robert Nelsen @rtnarch]

USA message should be “We want the best and brightest scientists and their families to come here. And stay here. And innovate here.” Getting our ass kicked by our adversaries in drones and robots and AI is not a fun option.

[Cathie Wood @CathieDWood]

Thank you, @Shea_ARK, for surfacing the potential value of one of the most important biology breakthroughs of our time: CRISPR gene editing. Many analysts seem to think that one-time cures will not be a good business, @ARK Invest begs to differ! $CRSP, $NTLA, $BEAM, $PRME

[BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech]

👀 shot > pill?
💉 > 💊 at a certain point

@bioinvestor24 cites an $ABBV survey that shows psoriasis pts prefer a q3m injection over a daily pill.

Analysts often assume “oral = convenient” for $KYMR in AD vs $APGE q3m shot. Reality is efficacy + freedom from daily dosing often trumps pill convenience.

At a certain point efficacy is NOT perceived as equal, where that standard deviation lies varies, but end of day patients want what works, not what’s easy.

[C. Michael Gibson MD @CMichaelGibson]

Lp(a) and me.

I share my story here to raise awareness about elevated Lp(a) … 20% of US adults have elevated levels of lipoprotein(a).

Know your number #cmgsays https://t.co/YUUvrp9kAM

[Samarth Kulkarni @CrisprSam]

Thank you! It’s a reflection of all the employees who are dedicated to the cause of bringing cures to patients!

[Yair Einhorn @yaireinhorn]

Congrats to @CrisprSam - the CEO of @CRISPRTX on being part of the TIME100’s Health list - honoring the 100 most influential people in health today. $CRSP is the first-ever company to receive an FDA approval for its Gene Editing treatment - CASGEVY. A well-deserved recognition!

[Samarth Kulkarni @CrisprSam]

Congrats @CRISPRTX on being named to the @TIME Most Influential Companies of 2025 list! Proud of the full company and excited for the future of genetic medicine. #CRISPRTX #TIME100Companies

[TIME @TIME]

Introducing TIME's most influential companies of 2025: 100 companies around the world that shaped culture, made new strides, reached milestones, and more https://t.co/VwDExA53dk

[Samarth Kulkarni @CrisprSam]

We are excited to announce our collaboration with Sirius Tx. This strategic partnership expands our therapeutic toolkit & broadens our cardiovascular portfolio. We look forward to working closely with the Sirius team to advance this exciting asset

[CRISPR Therapeutics @CRISPRTX]

Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. https://t.co/h4aG9TkNeR

[Samarth Kulkarni @CrisprSam]

Thank you @TIME for naming me on the #TIME100HEALTH list! Honored to be included and congrats to all the 2025 honorees. https://t.co/4QL0YP846Q

[TIME @TIME]

TIME's new cover: Meet this year's #TIME100Health, a community of leaders—scientists, doctors, advocates, educators, and policy-makers, among others—who are changing the health of the world. https://t.co/1MpFEK5mKo

[Samarth Kulkarni @CrisprSam]

Proud to share our latest business updates and positive top-line results from our Phase 1 clinical trial of CTX310 targeting ANGPTL3. Congratulations to our team and all who contributed to this milestone! @CRISPRTX

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

U.S. leadership in biotech is a national security, economic, and public health imperative.

With the attack on science and universities, instability at FDA, & weakening of the capital markets, we are at grave risk of ceding this leadership to China.

This must not happen!

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

This is a major setback for FDA, improvements in regulatory science, and advancement of innovation for patients! https://t.co/6eNCABhyAX